Kexiang Zhou
Managing Director @ CMB International Capital Corporation
Kexiang Zhou is a Series B investor at CMB International Capital Corporation focused on Health Care and Biotechnology. Kexiang Zhou received his Doctor’s degree from Peking University Health Science Center. He is a venture capitalist and entrepreneur in the healthcare space for more than 20 years.Currently serves as Managing director of CMB International healthcare investment. Under Kexiang Zhou’s leadership, CMBI healthcare team has invested over 1.5 billion RMBin more than 10 projects, with focus on gene technology, innovative drugs, medical instruments, generic drugs, etc.Former Deputy general manager of Guangzhou Pharmaceutical Holdings (“GPH”) and President of BaiYunShan General Factory (“BYS”), a public listed subsidiary of GPH, where he was responsible for the company’s R&D, production, quality control in the pharmaceutical sector, as well as the company’s international business and intermediates sector. During his stay, Kexiang Zhou has formed and developed the world largest medical commercial joint venture.Previously as a managing director and the chairman of investment committee in healthcare sector at CM Capital, oversaw the company’s healthcare investments.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Kexiang Zhou invests in
Stages Kexiang Zhou invests in
Countries Kexiang Zhou invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (100%)
- Biotechnology 2 (100%)
- Pharmaceutical 1 (50%)
Stage
- Series B 1 (50%)
- Series C 1 (50%)
Country
- China 1 (50%)
- United States 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
PackGene Biotech
|
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, wedeliver cost-effective, dependable, and scalable production solutions. | Series C / Apr 07, 2021 | |
Apollomics
|
Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several development-stage assets, including novel, humanizedmonoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. | $100M / Series B / Jan 08, 2019 |
Co-Investors
CMB International Capital Corporation is an investment banking firm that offers comprehensive professional services and financial advisory services. It provides mergers and acquisitions, initial public offering, equity underwriting, company restructuring, project financing, and business consulting services. CMB International Capital Corporationprovides corporate finance, asset management, wealth management and securities brokerage services. Additionally, it offers debt financing and transaction advisory services, placement of shares and refinancing for listed companies. CMB International Capital Corporation’s clientele include institutional, corporate and individual customers both domestic and overseas. It began operation in 1987, with its headquarters in Central in Hong Kong as a subsidiary of China Merchants Bank.
CMB International Capital Corporation Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Hongbo Wang
Chief Investment Officer
|
|||
|
Kexiang Zhou
Managing Director
|
|||
|
Xinghai Zeng
Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Kexiang Zhou invest in?
Kexiang Zhou invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kexiang Zhou?
Public channels for Kexiang Zhou include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kexiang Zhou last invest?
The most recent investment recorded for Kexiang Zhou closed in Apr 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
